Monitoring of anesthesia depth: During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).
Study summary
Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative consciousness (qCON) index and the quantitative nociceptive (qNOX) index. This device enables more precise monitoring of anesthesia depth, quantification of patients' anesthesia analgesia and stress levels, and reliable monitoring of responses to noxious stimulation. During tracheal intubation for general anesthesia, when the qCON value falls within the range of 40 to 60 and the qNOX value is between 30 and 50, it indicates that the patient is in an appropriate state of sedation and analgesia. However, there is currently no universally acknowledged standard for the optimal qNOX reference range during conscious sedation endoscopy. Therefore, this study utilizes the noxious stimulation response index (qNOX) to monitor noxious stimulation during the procedure, aiming to identify the best timing for inserting the endoscope during conscious sedation endoscopy and explore the appropriate range of qNOX for this purpose.
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria
1. Age between 18 and 60 years old;
2. ASA-PS (American Society of Anesthesiologists Physical Status) classification of I to II;
3. Body Mass Index (BMI): 18 to 28 kg/m²;
4. Patients undergoing diagnostic and therapeutic procedures under sedation for lower gastrointestinal endoscopy;
5. Clear understanding and voluntary participation in this study, with informed consent signed.
Exclusion Criteria
1. Patients requiring complex endoscopic techniques for diagnosis and treatment;
2. Patients who have participated in other clinical trials in the past three months;
3. Pregnant and lactating patients;
4. Patients with allergies to sedatives/anesthetics and other severe anesthesia risks;
5. Patients with preoperative chronic pain or a history of substance abuse;
6. Patients with severe neurological diseases such as stroke, hemiplegia, convulsions, epilepsy, etc.;
7. Patients with known difficult airways such as limited mouth opening, restricted neck and jaw movement, rheumatoid spondylitis, temporomandibular joint arthritis, etc.;
8. Patients with potentially life-threatening circulatory and respiratory diseases that are not adequately controlled, such as uncontrolled severe hypertension, severe arrhythmias, unstable angina pectoris, acute respiratory infections, asthma exacerbations, etc.;
9. Patients with liver dysfunction (Child-Pugh Class C or higher), acute upper gastrointestinal bleeding with shock, severe anemia, gastrointestinal obstruction with gastric retention.
Primary outcome measure(s)
The value of qNOX — Start of the procedure，when the gastroscope passes through the pharynx or the colonoscope passes through the anus. The value of qNOX when the gastroscope passes through the pharynx or the colonoscope passes through the anus.
Trial sites (1)
Facility
City
Region
Status
China,Chongqing The First Affiliated Hospital of Chongqing Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.